Dermatology Billing Services That Separate Medical From Cosmetic

Dermatology medical billing hinges on two things that trip up generalist billers constantly: lesion coding accuracy and the line between medical and cosmetic. Excision codes depend on whether a lesion is benign or malignant and on its measured size; biopsies and destructions have their own families; Mohs surgery bills in stages; and modifier 25 has to justify an evaluation on the same day as a procedure. Get the medical-necessity story wrong and a legitimate claim denies as cosmetic.

Lesion coding is where the dollars and the errors concentrate. An excision is coded by the lesion’s nature (benign vs. malignant, which often isn’t known until pathology returns) and by its size including margins — and both have to be captured accurately from the operative note. Round the size down, miscode the nature, or fail to update after pathology, and the claim underpays or denies. At the volume a dermatology practice generates, these small coding decisions add up quickly.

Mohs surgery is a specialty within the specialty. It’s billed in stages, with the surgeon acting as both surgeon and pathologist, and the staging has to be documented and coded precisely — a high-value service that’s frequently misbilled by those unfamiliar with its rules. Alongside it, biopsies (11102–11107) and their add-on codes have their own per-lesion logic.

Then there’s modifier 25 and the medical-cosmetic line. Dermatology visits routinely combine an evaluation with a same-day procedure, which requires a well-documented modifier 25 to bill both — a frequent audit target when used loosely. And because dermatology mixes covered medical care with elective cosmetic work, keeping the two cleanly separated protects both revenue and compliance.

What’s included, specifically:

• Biopsy and excision coding by nature (benign/malignant) and measured size
• Pathology-driven code updates so the final claim matches the diagnosis
• Mohs surgery staged billing, documented and coded precisely
• Modifier 25 for same-day E/M, supported by documentation
• Destruction, cryotherapy, and lesion-treatment coding
• Clean medical-vs-cosmetic separation on mixed visits
• Denial review focused on lesion coding and modifier 25 patterns

Pathology reconciliation is a step generic billing skips, and it costs dermatology practices real money. Because excision and biopsy codes often depend on whether a lesion turns out benign or malignant, the initial claim frequently has to be updated once pathology returns — and a practice that bills at the time of service and never revisits the claim can lock in the wrong, lower-paying code. RevPath reconciles lesion claims to the final pathology, so the code that gets billed matches the diagnosis that was actually made.

The medical-versus-cosmetic discipline protects the practice on both ends. Clean separation ensures covered medical care is billed to insurance and paid, while cosmetic work is handled as self-pay without muddying the medical claim — which keeps revenue flowing and keeps the practice out of the compliance gray zone that loose modifier 25 and cosmetic-coding habits create. For a busy dermatology office, that clarity is worth as much as the coding accuracy itself.

Consider a visit where a patient is evaluated for a new concern, has two suspicious lesions biopsied, and a benign lesion destroyed. Correct billing means the evaluation supported by modifier 25, each biopsy coded with its add-on logic, the destruction coded appropriately, and — once pathology returns — the codes reconciled to the actual diagnoses. A rushed claim under-captures the biopsies and drops the modifier. RevPath codes each element correctly and reconciles to pathology, which across a full dermatology schedule is the difference between clean, compliant collections and a steady trickle of denials.

This fits general and surgical dermatology practices and Mohs-focused specialty practices where lesion volume and procedure coding define the day. It leans on sharp denial management and precise medical coding on lesion and Mohs claims.

The outcome is denial rates that drop toward the low single digits from the 10–15% common when lesion coding is loose, cleaner audit posture on modifier 25, and full capture of biopsy and Mohs revenue — on top of the 25–35% revenue growth our track record covers.

In dermatology, the money and the compliance both live in the lesion coding. RevPath gets both right.